Tg Therapeutics, Inc.

This study tests whether ublituximab, given as an infusion, can help adults with myasthenia gravis maintain symptom control after initial treatment with efgartigimod. Participants will receive either ublituximab or a placebo, and researchers will track how long it takes for sympt…

This early study tests a new treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders like multiple sclerosis and neuromyelitis optica. The treatment uses a patient's own immune cells that are modified in a lab to target and destr…

This Phase 3 trial is testing a modified dosing schedule of ublituximab (BRIUMVI) in 800 people with relapsing multiple sclerosis. The study has three parts: one open-label part to see if the new regimen reduces brain lesions, a placebo-controlled part to measure drug levels, and…

This registry study will follow 2000 people with relapsing multiple sclerosis who are prescribed BRIUMVI (ublituximab-xiiy) in real-world settings. Researchers aim to track safety, effectiveness (like relapse rates), and the overall treatment experience. Participants must not hav…

This study looks at how much of the multiple sclerosis drug BRIUMVI gets into breast milk. About 16 breastfeeding women with relapsing MS will provide milk samples after their regular treatment. The goal is to understand drug exposure for nursing infants, not to test a new treatm…

This registry study follows pregnant women with multiple sclerosis (MS) who have taken BRIUMVI, comparing them to those who haven't taken the drug. The goal is to see if BRIUMVI increases the risk of major birth defects. Researchers will enroll about 728 participants across two g…